Der bør dog udvises forsigtighed når lumiracoxib administreres samtidig med substrater af CYP2C9, der har meget smalle terapeutiske indeks, så som phenytoin og warfarin.
However care should be exercised when lumiracoxib is co-administered with substrates of CYP2C9 that have very narrow therapeutic index, such as phenytoin and warfarin.